Marvel J, et al. - Individuals aged ≥ 12 years with ≥ three non-diagnostic outpatient or inpatient claims with a hidradenitis suppurativa (HS, a chronic, recurring, inflammatory disease of the skin and soft tissue identified by deep-seated nodules, sinus tracts and abscesses resulting in fibrosis in the axillary, inguinal, breast-fold and anogenital regions) diagnosis code and ≥ 12 months continuous recruitment with medical and pharmacy advantages prior to (preindex) and following (postindex) the earliest diagnosis of HS (index) were involved in order to analyze demographic/clinical features of patients with HS and treatment patterns, prevalence and healthcare resource utilization/expenditures associated with HS in the real-world. A total of 11,325 Commercial/Medicare patients and 5,164 Medicaid individuals were involved. Commercial/Medicare and Medicaid HS beneficiaries experienced great comorbidity burden however it used distinct treatment modalities to control HS. Moreover, among this patient population, a substantial unmet requirement endures, with Medicaid patients encountering an especially high burden of disease and expensive healthcare resource utilization.